MacroCure

Therapeutic Platform for Hard-to-Heal Wounds

Acquired (Inactive) by Leap Therapeutics on Jan 2017 - closed due to acquisition

Company Overview

Snapshot

Founded in January 2008, MacroCure operated with 1–10 employees, raising a total of $102 million across three funding rounds. The company was acquired by Leap Therapeutics in January 2017.

Business overview

MacroCure is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform for chronic and hard-to-heal wounds, including diabetic foot ulcers and venous leg ulcers. The company's core technology involves injecting the human body's own wound-healing and regenerative components directly into the wound. Its lead product candidate, CureXcell, is a combination of activated human white blood cells designed to facilitate healing and stimulate wound closure. MacroCure operates within the pharmaceuticals sector, serving the healthcare and life sciences markets with a focus on regenerative medicine and cell therapy.

Strategic signal

In January 2017, MacroCure completed a merger with Leap Therapeutics. This strategic move indicates a significant shift in the company's operational structure and future direction, signaling to investors a consolidation within the biopharmaceutical space and a potential for combined resources to advance therapeutic development.

Company Intelligence Q&A

What is MacroCure's primary therapeutic focus?
MacroCure focuses on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers.
What is CureXcell?
CureXcell is MacroCure's lead product candidate, a combination of living human white blood cells activated to facilitate the healing process and stimulate wound closure.
When did MacroCure complete its merger with Leap Therapeutics?
MacroCure completed its merger with Leap Therapeutics in January 2017. This strategic move combined the two biopharmaceutical companies, with MacroCure being acquired by Leap Therapeutics.
What was a significant financial event for MacroCure in August 2014?
In August 2014, MacroCure completed an Initial Public Offering on NASDAQ, raising $54 million.
Which investors participated in MacroCure's May 2012 funding round?
In May 2012, MacroCure received funding from Rainfall Ventures and Jerusalem Global Ventures.

External links